BioArctic flags new press release on Leqembi subcutaneous autoinjector data at AAIC 2026
BIIB•PK bioequivalence data
Data highlighted PK bioequivalence for weekly 500 mg SC dosing versus 10 mg/kg IV every two weeks, with an exposure ratio of 104%.
AAIC 2026 update on Leqembi autoinjector
BioArctic posted an AAIC 2026 update on Leqembi’s subcutaneous autoinjector, positioning efficacy and safety as comparable to the IV regimen.
Potential at-home administration pathway
The release pointed to a potential at-home administration pathway, aiming to broaden access through a fully subcutaneous initiation-to-maintenance option.
